News

Amgen acquires all the shares of Amgen Astellas Biopharma

Read time: 1 mins

Published:7th Mar 2020

Amgen Inc., Astellas Pharma Inc. and Amgen Astellas BioPharma K.K. announced that on April 1, 2020, Amgen will purchase the 49% of shares in Amgen Astellas BioPharma that are held by Astellas, based on the strategic alliance contract signed between Amgen and Astellas in 2013, making the company a wholly owned Amgen affiliate. With this, Amgen Astellas BioPharma will change its name to Amgen K.K., and simultaneously relocate its Headquarters to Tokyo Midtown (9-7-1 Akasaka, Minato-ku, Tokyo). Steve Sugino will continue to serve as President and Representative Director of Amgen K.K.

Type: industry

Learning Zone Homepage

Advances in HS

The latest updates in HS from the 2024 European Hidradenitis Suppurativa Foundation Conference, 7–9 February in Lyon

Learning Zone

All Things Angioedema and Urticaria: Podcasts

In these podcasts, our hosts, Professor Marcus Maurer and Dr Thomas Buttgereit are joined by friends and colleagues to discuss all things related to angioedema and urticaria.

Learning Zone Homepage

Ulcerative colitis Learning Zone

Explore the role of biologics and targeted small molecules in UC management, and listen to expert insights on integrating them into practice.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

FDA accepts NDA for SH 201 the first palatable oral liquid of the related chemotherapeutic agent, for the treatment of certain forms of leukemia and other cancers

The FDA has accepted the new drug application (NDA) for SH 201, the first palatable oral liquid of the related chemotherapeutic agent, for the treatment of certain forms of leukemia and other cancers

1 mins

Drug news

Sphere 360 pulse field ablation catheter, a new paradigm in single-shot ablation, demonstrates impressive results in treating paroxysmal atrial fibrillation

Medtronic plc, announced positive clinical trial safety and efficacy results for Sphere-360 , an investigational single-shot mapping and ablation catheter using pulsed field (PF) energy, for treatment of patients with paroxysmal atrial fibrillation (AFib)

2 min

Drug news

Toripalimab + axitinib combination approved in China for frontline renal cell carcinoma

The National Medical Products Administration of China has approved toripalimab combined with axitinib (Inlyta) for use in the first-line treatment of patients with medium- to high-risk unresectable or metastatic renal cell carcinoma (RCC)

1 min

See all news